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Introduction 30
Cytokinetic abscission is the final stage of cell division when the newly formed 31 daughter cells are irreversibly separated. Abscission is a multi-step process that culminates 32 in the resolution of the midbody, the thin intercellular bridge that connects dividing cells 33 following mitosis (1-3). The final membrane fission step of abscission is mediated by the 34 Endosomal Sorting Complexes Required for Transport (ESCRT) pathway (4-7). The ESCRT 35 machinery comprises membrane-specific adaptors and five core factors/complexes (ALIX, 36 checkpoint is governed by the master regulator, Aurora B kinase, which inhibits ESCRT-III 48 activity in response to mitotic problems. Two key intersecting signaling nodes within this 49 pathway are the ESCRT-III subunit CHMP4C and the regulatory ULK3 kinase. CHMP4C is a 50 specialized ESCRT-III subunit that is dispensable for cytokinetic membrane fission, viral 51 budding and endosomal sorting, but plays an essential role in executing the abscission 52 checkpoint (20, 21). CHMP4C is directly phosphorylated by Aurora B and is further 53 phosphorylated by ULK3, which also phosphorylates other ESCRT-III subunits such as IST1. 54 CHMP4C phosphorylation and ULK3 activity, together with the actions of other ESCRT-III-55 associated factors such as ANCHR, collectively prevent ESCRT-III polymerization and 56 sequester VPS4 away from abscission sites, thereby delaying abscission (20, 22, 23) . 57
Despite recent advances in identifying key components of the abscission checkpoint, 58 the biological functions of the checkpoint and its contributions to human health are not yet 59 known. Here, we have addressed these questions by analyzing the biochemical and 60 abscission checkpoint activities of rs35094336, a human CHMP4C polymorphism (minor 61 allele frequency [MAF]=0.04) associated with increased susceptibility to ovarian cancer (24). 62 rs35094336 encodes an amino acid substitution of A232 (CHMP4C A232 ; reference allele) to 63 T232 (CHMP4C T232 ; risk allele). Here, we show that the A232T substitution induces structural 64 changes that impair ALIX binding and that cells expressing the CHMP4C T232 risk allele lack 65 an abscission checkpoint and accumulate genetic damage. The CHMP4C T232 allele also 66 sensitizes cells to chromosome mis-segregation and induces aneuploidy when the spindle 67 assembly checkpoint is weakened. These observations demonstrate the importance of the 68 abscission checkpoint in maintaining genetic stability and suggest a novel oncogenic 69 mechanism in which disruption of the abscission checkpoint by CHMP4C T232 may contribute 70 to tumorigenesis by synergizing with oncogenic mutations that increase mitotic stress. 71
Results 72 CHMP4C T232 is associated with multiple cancer types 73
The CHMP4C T232 allele was initially identified in a meta-analysis of two genome wide 74 association studies (GWAS) of single nucleotide polymorphisms associated with ovarian 75 cancer (24). To test for an association of the CHMP4C T232 polymorphism with other cancers, 76
we mined data from 337,208 individuals in the UK Biobank search engine (25). Our analysis 77 of this independent cohort confirmed the previously identified association with ovarian 78 cancer, and revealed statistically significant associations with multiple other types of cancer, 79
including male genital tract, prostate, and skin (Table 1) . Although the odds ratios for these 80 associations are relatively modest (1.04-1.17), association of the variant with increased risk 81 for multiple different cancers suggests that this allele could be involved in a general pathway 82 toward genetic instability and tumorigenesis. 83
84

CHMP4C T232 exhibits reduced ALIX binding 85
Position 232 is the penultimate CHMP4C residue, and A232 lies within a C-terminal 86 helix that forms the ALIX binding site (26). We therefore tested whether the A232T amino 87 acid substitution affected ALIX binding, and found that this substitution significantly reduced 88 the interaction between full length CHMP4C and ALIX (but not CHMP4C and itself) in a yeast 89 two-hybrid assay (Fig. 1A ). This substitution similarly inhibited the ability of a GST-fused C-90 terminal CHMP4C peptide (residues 216-233) to pull down endogenous ALIX from HeLa cell 91 lysates ( Fig. S1A ) and reduced the affinity of the terminal CHMP4C peptide for the pure 92 recombinant ALIX Bro1 domain (residues 1-359) by 13-fold as measured in a competitive 93 fluorescence polarization binding assay ( Fig. 1B) . In each case, we observed complete loss 94 of ALIX binding to well-characterized control CHMP4C mutants that lacked key hydrophobic 95 contact residues (L228A and/or W231A)(26). 96
To determine the molecular basis for this reduction in ALIX binding affinity, we 97 determined high-resolution crystal structures of terminal CHMP4C A232 and CHMP4C T232 98 peptides (residues 216-233) bound to the ALIX Bro1 domain (residues 1-359) ( Fig. 1C and 99 between the W231 carbonyl oxygen and indole nitrogen with ALIX residues D143 and K147, 105 respectively ( Fig. 1D ). These structural analyses suggested that the A232T substitution might 106 induce CHMP4C helix unwinding by introducing a beta-branched amino acid (which reduces 107 helical propensity) and/or by prematurely capping the CHMP4C C-terminal helix (27). Indeed, 108 both of these effects appeared to be operative because mutant CHMP4C peptides that 109 selectively retained only beta-branching (CHMP4C A232V ) or capping potential (CHMP4C A232S ) 110 exhibited intermediate (3-4-fold) reductions in ALIX peptide binding affinity ( Fig. 1B) . 111
Together, these analyses demonstrate that the CHMP4C T232 risk allele alters the structure of 112 the CHMP4C C-terminal helix, removes key ALIX interactions, and reduces ALIX binding 113 affinity by more than an order of magnitude. 114
115
ALIX-CHMP4C interactions are required for abscission checkpoint activity 116
ALIX is a key initiator of the cytokinetic abscission cascade (4, 5, 11, 28), and 117 CHMP4C plays an essential role in maintaining the abscission checkpoint (4, 20, 21). We 118 therefore tested whether abscission checkpoint activity was affected by CHMP4C mutations 119 that impaired ALIX binding, including the CHMP4C T232 risk allele. In these experiments, 120 siRNA treatment was used to deplete endogenous CHMP4C from HeLa cells engineered to 121 stably express different siRNA-resistant HA-CHMP4C proteins ( Fig. 2, and Fig. S2 ). Partial 122 depletion of nuclear pore components Nup153 and Nup50 was used to activate the 123 abscission checkpoint. As expected, control cells that expressed endogenous CHMP4C 124 stalled during abscission, as indicated by elevated midbody connections, whereas cells 125 depleted of CHMP4C did not exhibit elevated levels of midbody connections (20, 29) ( Fig.  126 2A, Fig. S2A ). Importantly, checkpoint activity was rescued in cells that expressed HA-127 CHMP4C A232 but not in cells that expressed HA-CHMP4C T232 , implying that the CHMP4C T232 128 risk allele does not support the abscission checkpoint. The HA-CHMP4C L228A,W231A mutant 129 also failed to support the abscission checkpoint, further indicating that the CHMP4C-ALIX 130 interaction is required to sustain the checkpoint. Notably, the loss of checkpoint activity for 131 both HA-CHMP4C L228A,W231A and HA-CHMP4C T232 was comparable to the defective response 132 observed in cells that expressed an inactive control CHMP4C mutant lacking the amino acid 133 insertion phosphorylated by Aurora B (HA-CHMP4C -INS )(20, 21). Similarly, cells expressing 134 only HA-CHMP4C T232 , HA-CHMP4C L228A,W231A or HA-CHMP4C -INS also proceeded through 135 abscission more rapidly under normal growth conditions, implying that they were insensitive 136 to steady-state abscission checkpoint activity, likely induced by midbody tension (23, 30) 137 ( Fig. 2B, Fig. S2B , Movies S1-S6). Despite these defects, HA-CHMP4C A232 , HA-138 CHMP4C T232 , HA-CHMP4C L228A, W231A and HA-CHMP4C -INS were all recruited to the midbody 139 at normal levels, whether or not nucleoporins were depleted (Fig. 2D, E) . Additionally, 140 CHMP4C ALIX-binding mutants and wildtype CHMP4C proteins were mitotically 141 phosphorylated at comparable levels ( Fig. S2D) , indicating that the CHMP4C mutations did 142 not disrupt recognition by Aurora B or ULK3 kinases, and that ALIX binding is not required for 143 these activities. These observations imply that abscission checkpoint activity requires ALIX 144 binding to CHMP4C. We find, however, that CHMP4C midbody localization does not require 145 ALIX binding, in contrast to a previous report (28) . 146
To test CHMP4C T232 activity when the abscission checkpoint was activated by a 147 different trigger, we used live cell imaging to measure the resolution times of intercellular 148 chromatin bridges, as visualized using the nuclear envelope marker lamina-associated 149 polypeptide 2β fused to YFP (YFP-LAP2β). As expected (20), chromatin bridges were 150 resolved prematurely in CHMP4C-depleted cells compared to cells that expressed 151 endogenous CHMP4C A232 (median resolution time = 250 vs 685 min, Fig. 2C , Fig. S2C , 152
Movies S7-S12). Importantly, normal midbody resolution times were restored by expression 153 of siRNA-resistant HA-CHMP4C A232 (800 min), but not by HA-CHMP4C T232 (200 min), HA-154 CHMP4C L228A,W231A (300 min) or HA-CHMP4C -INS (340 min). Thus, cells expressing the 155 cancer-associated CHMP4C T232 risk allele lack an appropriate abscission checkpoint 156 response under multiple different conditions that activate this checkpoint. 157 158
Disruption of the abscission checkpoint leads to accumulation of DNA damage 159
Although the biological consequences of abscission checkpoint loss are not well 160 understood, increased DNA damage is one possible outcome (20). We therefore compared 161 DNA damage accumulation in cells that expressed the different CHMP4C mutants. In these 162 experiments, CRISPR-Cas9 was used to delete the CHMP4C locus from HCT116 cells ( Fig.  163 S3), a near diploid cell line that exhibits low levels of chromosomal instability and DNA 164 damage (31). Genetic damage was then assessed by scoring the number of nuclear foci 165 formed by the DNA damage response marker 53BP1. As expected, cells with low levels of 166 DNA damage predominated in the wild type cultures (HCT116 WT ) (<2 foci/cell) ( Fig. 3A, B) . In 167 contrast, cells lacking CHMP4C (HCT116 δCHMP4C ) exhibited heightened DNA damage (>6 168 foci/cell) with significantly greater frequency. Crucially, DNA damage in the HCT116 δCHMP4C 169 cells was reduced to control levels upon re-expression of HA-CHMP4C A232 , but not HA-170 To determine whether observed phenotypes were specifically due to abscission 177 checkpoint failure, we examined other mechanisms that might underlie the elevated levels of 178 DNA damage in HCT116 δCHMP4C cells. We ruled out ESCRT-dependent loss of nuclear 179 envelope integrity (32, 33) because nuclear envelope compartmentalization was not 180 compromised during telophase in cells lacking CHMP4C, as assayed by nuclear morphology 181 and retention of a GFP-NLS reporter ( Fig. S4 and Movies S13-S15). Similarly, loss of 182 CHMP4C did not globally impair DNA damage responses because the efficiency of G2/M cell 183 cycle arrest in response to genotoxic stress induced by the DNA cross-linker mitomycin C 184 was normal in HCT116 δCHMP4C cells (Fig. S5 ). Furthermore, in contrast to another report (34), 185
we did not observe a failure of HCT116 δCHMP4C cells to arrest in response to spindle poisons 186 such as nocodazole, indicating that the spindle assembly checkpoint remains largely intact in 187 these cells ( Fig. S6 ). Therefore, the increased DNA damage in cells lacking CHMP4C activity 188 and a functional abscission checkpoint does not reflect loss of nuclear integrity, improper 189 DNA damage responses or defective mitotic spindle assembly checkpoint signaling but 190 rather a loss of the abscission checkpoint. 191
192
CHMP4C T232 sensitizes cells to replication stress 193
We next examined the possibility that cells lacking CHMP4C activities had increased 194 levels of DNA damage because they were unable to respond properly to DNA replication 195 stress. This is an attractive model because: 1) a significant fraction of 53BP1 nuclear bodies 196 originate from lesions generated by DNA replication stress (35), 2) elevated replication stress 197 triggers the abscission checkpoint in a CHMP4C-dependent manner (18) (Fig. 3C ), and 3) 198 the abscission checkpoint plays a key role in protecting anaphase bridges that arise from 199 replication stress (36), thereby reducing damage when they persist during cytokinetic 200 abscission (37). In agreement with this model, inducing replication stress with ultra-low doses 201 (30 nM) of the DNA polymerase inhibitor aphidicolin reduced the proliferation of 202 HCT116 δCHMP4C cells nearly 2-fold as compared to HCT116 WT cells ( Fig. 3D ). Importantly, the 203 HCT116 δCHMP4C growth defect was again rescued by expression of HA-CHMP4C A232 , but not 204 by the abscission checkpoint defective, HA-CHMP4C T232 , HA-CHMP4C L228A,W231A or HA-205 CHMP4C -INS mutants. Thus, the abscission checkpoint can play a protective role in cell 206 survival when cells are subjected to increased replication stress. 207 208
CHMP4C T232 sensitizes cells to chromosome mis-segregation and induces aneuploidy 209
To examine the functions of the abscission checkpoint in the context of another mitotic 210 stress, we tested whether a defective abscission checkpoint also sensitized cells to 211 weakening of the spindle assembly checkpoint (SAC), a condition that induces anaphase 212 chromosomal segregation errors. The SAC was selectively weakened by treatment with low 213 doses (0.1 µM) of the MPS1 kinase inhibitor reversine (38), which doubled the frequency of 214 anaphase chromosome mis-segregation ( Fig. 4A, Fig. S7B , Movies S16-19) and activated 215 the abscission checkpoint in a CHMP4C-dependent fashion (Fig. S7A ). Karyotyping of 216 metaphase spreads revealed that HCT116 WT cells only rarely displayed extreme aneuploidy 217 (1% of DMSO-treated cells had <37 or >48 chromosomes, Fig. 4B, C) . Reversine treatment 218 alone increased this percentage, but cells with extreme aneuploidy were still rare (7%). In 219 contrast, DMSO treated HCT116 δCHMP4C cells exhibited a higher basal level of extreme 220 aneuploidy (4%), and this percentage increased notably upon reversine treatment (23%). Re-221 expression of HA-CHMP4C A232 , but not HA-CHMP4C T232 protected against reversine induced 222 increases in aneuploidy ( Fig. S8A ). Importantly, reversine treatment in cells with a defective 223 abscission checkpoint did not induce a multinucleation phenotype, but these cells did display 224 a higher proportion of micronuclei ( Figure S8B ). Our observations that CHMP4C mutations can abolish the abscission checkpoint and 237 that these mutations synergize with increases in chromosome mis-segregation raised the 238 intriguing possibility that such mutations might also synergize with genetic alterations known 239 to be associated with ovarian cancer development. We focused our studies on TP53, the 240 most frequently mutated gene in a wide range of cancers, including >96% of high-grade 241 serous ovarian tumors (40). In addition to its classical role in inducing cell cycle arrest in 242 response to DNA damage, p53 also functions directly in DNA damage repair and 243 chromosomal stability, and its absence is associated with increased replicative stress (41). 244
As expected, stable depletion of p53 increased DNA damage levels as measured by 245 increased numbers of 53BP1 foci ( Fig. S9B, C) and increased frequencies of chromosomal 246 segregation defects during anaphase ( Fig. 4D, S7D , Movies S20-S23). As with reversine 247 treatment, these defects significantly compromised HCT116 cell growth only when CHMP4C 248 was absent (Fig. 4E, bottom panel, Fig. S9A ). This synergistic effect was again reversed 249 upon re-expression of CHMP4C A232 but not HA-CHMP4C T232 , HA-CHMP4C L228A,W231A or HA-250 CHMP4C -INS (Fig. 4E, bottom panel, Fig. S9A ). Thus, loss of the CHMP4C-dependent 251 abscission checkpoint also synergizes with loss of functional p53. This effect can again be 252 explained by an inability of cells to cope with the increased burden of chromosomal 253 segregation defects, perhaps compounded further by dysfunction of the p53-mediated G1 254 checkpoint (42). 255 256
Discussion 257
Our study demonstrates that the abscission checkpoint plays a critical role in human 258 health by protecting the genome against DNA damage and chromosomal instability. We have 259
shown that a human polymorphism in CHMP4C, previously associated with increased 260 susceptibility to ovarian cancer, is also associated with increased risk for several other 261 cancers, thus suggesting that the CHMP4C T232 allele contributes to tumor development in a 262 global fashion. Importantly, cells that express the cancer-associated CHMP4C T232 allele show 263 elevated levels of 53BP1 foci, suggesting that increased DNA damage may account, at least 264 in part, for increased cancer susceptibility in individuals who carry this allele. Furthermore, 265 cells that express CHMP4C T232 are particularly sensitized to genomic instability under 266 conditions that increase the burden of chromosomal segregation defects, such as DNA 267 replication stress and weakening of the spindle assembly checkpoint. indirectly. This idea is consistent with the observation that autoinihibition of Snf7p, the yeast 282 orthologue of CHMP4, can be relieved by removing its terminal Bro1p (ALIX) binding helix 283 (44-46). We do not yet know for certain why CHMP4C-ALIX binding is required to support the 284 abscission checkpoint, but one intriguing possibility is that CHMP4C binding may 285 competitively inhibit CHMP4B from occupying its overlapping binding site on ALIX (26), 286 thereby sustaining the abscission checkpoint by preventing nucleation of CHMP4B-287 containing ESCRT-III filaments within the midbody. 288
Another striking finding of our study is that increasing chromosomal segregation 289 defects in cells lacking a functional abscission checkpoint specifically induces high levels of 290 aneuploidy and chromosomal instability. Although complete inhibition of Aurora B leads to 291 cleavage furrow regression and binucleation when chromatin is present in the intracellular 292 bridge (17), this mechanism does not appear to explain the increases in aneuploidy when 293 Chromosomal segregation errors are a hallmark of many cancers and often arise in 318 response to oncogenic mutations that increase mitotic stress (39). In particular, loss of p53 is 319 the most common genetic abnormality in many tumor types, and can lead to increased DNA 320 damage, chromosomal instability, and increased replicative stress (40, 41, 50). These 321 phenotypes suggest a potential mechanism by which loss of the abscission checkpoint could 322 contribute to genetic instability and cancer development, particularly as we observed 323 synthetic lethality between loss of p53 and the CHMP4C T232 risk allele. Our data suggest the 324 possibility that homozygous germline expression of the CHMP4C T232 allele -or loss of 325 heterozygosity of CHMP4C A232 encoding allele expression in somatic cells where the T232 326 encoding allele is present -could contribute to tumorigenesis by increasing genomic 327 instability and aneuploidy, particularly when chromosome mis-segregation events are 328 elevated. We speculate that although an impaired abscission checkpoint combined with 329 genetic alterations such as p53 loss is detrimental to overall cell growth, the subset of cells 330 that ultimately survive may accumulate further adaptations that promote tumorigenicity. 331
These cells may nevertheless remain sensitive to further perturbations of chromosome 332 segregation or DNA damaging agents and this sensitivity could, in principle, be exploited 333 therapeutically. In this regard, it is noteworthy that CHMP4C depletion increases the 334 effectiveness of irradiation-induced apoptosis in human lung cancer cells (51) and that many 335 common chemotherapeutic drugs such as Paclitaxel act, at least in part, by increasing 336 chromosome mis-segregation (39). Hence, we speculate that such chemotherapeutics may 337 be particularly effective in patients who carry the CHMP4C T232 allele. 338
Methods 339 340
Plasmids and antibodies: 341
Details of plasmids and antibodies used in this study are described in Table S2 . Table S2 . Healthcare). Details on antibodies and dilutions can be found in Table S2 . 399 400
Immunofluorescence: 401
Cells were grown on coverslips, washed once in PBS and fixed for 10-20 minutes in ice cold 402 methanol. Cells were blocked with 3% FCS, 0.1% Triton X-100 in PBS for 20 minutes. 403
Primary antibodies were applied for at least 1 hour. After washing 4X with PBS, secondary 404 antibodies were applied for 1 hour and nuclei were stained with either Hoechst or 4′,6-405 diamidino-2-phenylindole (DAPI). Coverslips were mounted with ProLong Gold Antifade 406 Reagent (Invitrogen) on a microscope slide. Images were acquired using a Leica SP8 407 Confocal (Fig. 2D) or Nikon Ti-Eclipse wide-field inverted microscope (Fig. 3, S4, S2) . 408
Scoring was conducted blind. Where indicated, deconvolution was performed using 409
HyVolution Pro-Automatic deconvolution software. Quantification of fluorescence staining 410 intensity was carried out with ImageJ. The freehand selection tool was used to outline the 411 region of interest and staining intensity within this area was measured. Signals were 412 background corrected using measurements from adjacent regions. Details on antibodies and 413 dilutions can be found in Table S2 . was identified through co-localization with H2B-mCherry, and was normalized to the 431 cytoplasmic signal. Signals were background corrected using measurements from adjacent 432 regions. Measurements were taken 10 frames before and 50 frames after nuclear envelope 433 breakdown, with cells depleted of CHMP7 serving as a positive control (56). 434 435
Protein expression and purification: 436
The human ALIX Bro1 domain (residues 1-359, Fig. 1C, D, Fig S1) and ALIX Bro1-V 437 domains (residues 1-698, Fig. 1B ) were expressed and purified as previously described with 438 minor modifications (27, 57) . A detailed description is provided by SI Materials and Methods. 439
Plasmids for bacterial expression of ALIX proteins are available from the Addgene plasmid 440 repository (www.addgene.org; see Table S2 for accession numbers). 10% PEG 20,000, 100 mM MES, pH 6.5; CHMP4C T232 : 15% PEG 8,000, 100 mM MES, pH 447 6.5, 200 mM sodium acetate). Crystals were flash frozen in nylon loops in cryo-protectant 448 composed of reservoir solutions containing 30% glycerol. Data were collected remotely (58) 449 (0.9794 Å wavelength, 100°K) at the Stanford Synchrotron Radiation Lightsource (SSRL) on 450 beamline 12-2 using a Dectris Pilatus 6M detector. Data were integrated and scaled using 451
AutoXDS (59-61). Both complexes crystallized in space group C121 with one ALIX-452
Bro1:CHMP4C complex in the asymmetric unit. The crystals diffracted to 1.91 Å (ALIX Bro1-453 CHMP4C A232 ) and 1.87 Å (ALIX Bro1-CHMP4C T232 ) resolution. For data collection and 454 refinement statistics see Table S1 . 455 456
Structure determination and refinement: 457
A model for molecular replacement was generated from the previously determined structure 458 of the ALIX Bro1-CHMP4C A232 complex (PDB 3C3R) (26) by removing the coordinates for the 459 CHMP4C peptide and using the ALIX Bro1 structure as a search model (Phaser in PHENIX) 460 (62, 63). CHMP4C helices were built de novo into the electron density for both structures 461
using Coot (64), and further refined in Phenix (65, 66) using TLS refinement strategies (67). For analysis of cell growth following p53 depletion, cells were transduced with either control 477 or p53 shRNA for 48 hours, then antibiotic selected for a further 48 hours. Transduced cells 478
were seeded at a density of 2.5 x 10 4 cells in a single well of a 24 well plate, cell number was 479 determined at 2, 4, or 7 days. Cell number was determined by manual counting and cells 480
were re-seeded in to 12 well plates on day 2, or 6 well plates on day 4. Inc.). All gating was applied manually. For mitotic arrest experiments all conditions were 506 performed in duplicate and samples were retained for immunoblotting analysis. 507 508
Analysis of publicly available cancer genome-wide association studies in the UK 509
Biobank: 510
To determine if the CHMP4C rs35094336 variant is also associated with other cancer types 511 we analyzed the publicly available data from 337,208 individuals in the UKBiobank engine. 512
Results were obtained from Global Biobank Engine, Stanford, CA (URL: 513 http://gbe.stanford.edu/) [October, 2017] . We used the following procedure to define cases 514 and controls for cancer GWAS. Individual level ICD-10 codes from the UK Cancer Register, 515
Data-Field 40006, and the National Health Service, Data-Field 41202 in the UK Biobank were 516 mapped to the self-reported cancer codes, Data-Field 20001 as described previously (68). 517
Positive associations are displayed in Fluorescence Microscopy Core Facility at the University of Utah for access to imaging 531 equipment, which was obtained using a NCRR Shared Equipment Grant 1S10RR024761-01. 532
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